Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators... see more

TSX:QIPT - Post Discussion

Quipt Home Medical Corp > QIPT Share Price projected upwards of 90% in 2022
View:
Post by CashFlowRanger on Nov 30, 2021 11:02am

QIPT Share Price projected upwards of 90% in 2022

https://seekingalpha.com/article/4472437

According to the article summary:

*QIPT shares started 2021 strong, but likely dipped due to multiple headwinds, including a warrant overhang and possible tax-loss selling.

*Two recent announcements should bode well for the stock as we enter the new year, with the distinct possibility that QIPT will be added to the Russell 2000 in June.

* QIPT’s AEBITDA guidance run rate means the stock is valued at roughly 5x forward EBITDA, with plenty of additional revenue growth opportunities and the prospect of expanding margins still ahead.

* While investors have previously been cautious due to the possibility of a capital raise to fund accretive acquisitions, the recent extension of their line of credit from $20M to $100M signals the company is prepared to use cheap debt instead.

* Based on my valuation metrics, I believe the stock could rally as much as 90% higher in the next six monthswith the possibility of 230% returns over the next three years, with little downside risk.

Hold on to your shares guys and gals, and if you can, buy some more. QIPT is looking strong in 2022!
Comment by lscfa on Nov 30, 2021 11:19am
Having too little debt is sub-optimal resulting in a lower ROE.  Quipt's competitors -- Apria, Rotech and Adapthealth -- having much more debt in their capital structures.